Compositions and methods for reducing methane emissions in ruminant populations
US-2024009291-A1 · Jan 11, 2024 · US
Controlled release coat-core tablet
US8968779B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8968779-B2 |
| Application number | US-201113704345-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 15, 2011 |
| Priority date | Jun 16, 2010 |
| Publication date | Mar 3, 2015 |
| Grant date | Mar 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Disclosed is a controlled release nucleated tablet which is composed of an inner nucleus and an outer layer that covers the inner nucleus and is capable of maintaining the level of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid in the blood to a certain value or higher for a long period of time. The controlled release nucleated tablet is characterized in that the inner nucleus contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and the outer layer contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and a gel-forming water-soluble polymer that is in an amount of 16 (w/w) % or more relative to the weight of the outer layer.
First claim
Opening claim text (preview).
The invention claimed is: 1. A controlled release tablet comprising an inner core and an outer layer portion covering the inner core, wherein the inner core contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid and the outer layer portion is a sustained release matrix layer and contains 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazole carboxylic acid and a gel-forming water-soluble polymer in an amount of 16% (w/w) or more with respect to the weight of the…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Human Necessities · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8968779B2 cover?
- Disclosed is a controlled release nucleated tablet which is composed of an inner nucleus and an outer layer that covers the inner nucleus and is capable of maintaining the level of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid in the blood to a certain value or higher for a long period of time. The controlled release nucleated tablet is characterized in that the inner nucle…
- Who is the assignee on this patent?
- Fujinaga Kentaro, Maruo Susumu, Nakamura Hideaki, and 4 more
- What technology area does this patent fall under?
- Primary CPC classification A61K9/209. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).